251 related articles for article (PubMed ID: 26929372)
1. Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomas.
Ebbesen SH; Scaltriti M; Bialucha CU; Morse N; Kastenhuber ER; Wen HY; Dow LE; Baselga J; Lowe SW
Proc Natl Acad Sci U S A; 2016 Mar; 113(11):3030-5. PubMed ID: 26929372
[TBL] [Abstract][Full Text] [Related]
2. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
Wang Q; Liu P; Spangle JM; Von T; Roberts TM; Lin NU; Krop IE; Winer EP; Zhao JJ
Oncogene; 2016 Jul; 35(27):3607-12. PubMed ID: 26500061
[TBL] [Abstract][Full Text] [Related]
3. Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma.
Marsh Durban V; Deuker MM; Bosenberg MW; Phillips W; McMahon M
J Clin Invest; 2013 Dec; 123(12):5104-18. PubMed ID: 24200692
[TBL] [Abstract][Full Text] [Related]
4. PTEN deficiency in a luminal ErbB-2 mouse model results in dramatic acceleration of mammary tumorigenesis and metastasis.
Schade B; Rao T; Dourdin N; Lesurf R; Hallett M; Cardiff RD; Muller WJ
J Biol Chem; 2009 Jul; 284(28):19018-26. PubMed ID: 19435886
[TBL] [Abstract][Full Text] [Related]
5. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
6. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
[TBL] [Abstract][Full Text] [Related]
7. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA
Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840
[TBL] [Abstract][Full Text] [Related]
8. Transforming acidic coiled coil 1 promotes transformation and mammary tumorigenesis.
Cully M; Shiu J; Piekorz RP; Muller WJ; Done SJ; Mak TW
Cancer Res; 2005 Nov; 65(22):10363-70. PubMed ID: 16288026
[TBL] [Abstract][Full Text] [Related]
9. Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines.
Fan P; McDaniel RE; Kim HR; Clagett D; Haddad B; Jordan VC
Eur J Cancer; 2012 Dec; 48(18):3488-98. PubMed ID: 22658320
[TBL] [Abstract][Full Text] [Related]
10. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers.
Liu Z; Hou P; Ji M; Guan H; Studeman K; Jensen K; Vasko V; El-Naggar AK; Xing M
J Clin Endocrinol Metab; 2008 Aug; 93(8):3106-16. PubMed ID: 18492751
[TBL] [Abstract][Full Text] [Related]
11. The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer.
Mimura K; Shiraishi K; Mueller A; Izawa S; Kua LF; So J; Yong WP; Fujii H; Seliger B; Kiessling R; Kono K
J Immunol; 2013 Dec; 191(12):6261-72. PubMed ID: 24244023
[TBL] [Abstract][Full Text] [Related]
12. Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN.
Pianetti S; Arsura M; Romieu-Mourez R; Coffey RJ; Sonenshein GE
Oncogene; 2001 Mar; 20(11):1287-99. PubMed ID: 11313873
[TBL] [Abstract][Full Text] [Related]
13. Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells.
Marty B; Maire V; Gravier E; Rigaill G; Vincent-Salomon A; Kappler M; Lebigot I; Djelti F; Tourdès A; Gestraud P; Hupé P; Barillot E; Cruzalegui F; Tucker GC; Stern MH; Thiery JP; Hickman JA; Dubois T
Breast Cancer Res; 2008; 10(6):R101. PubMed ID: 19055754
[TBL] [Abstract][Full Text] [Related]
14. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling.
She QB; Solit D; Basso A; Moasser MM
Clin Cancer Res; 2003 Oct; 9(12):4340-6. PubMed ID: 14555504
[TBL] [Abstract][Full Text] [Related]
15. PTEN suppression of YY1 induces HIF-2 activity in von-Hippel-Lindau-null renal-cell carcinoma.
Petrella BL; Brinckerhoff CE
Cancer Biol Ther; 2009 Jul; 8(14):1389-401. PubMed ID: 19483472
[TBL] [Abstract][Full Text] [Related]
16. Fish oil targets PTEN to regulate NFkappaB for downregulation of anti-apoptotic genes in breast tumor growth.
Ghosh-Choudhury T; Mandal CC; Woodruff K; St Clair P; Fernandes G; Choudhury GG; Ghosh-Choudhury N
Breast Cancer Res Treat; 2009 Nov; 118(1):213-28. PubMed ID: 18953692
[TBL] [Abstract][Full Text] [Related]
17. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
Fu X; Creighton CJ; Biswal NC; Kumar V; Shea M; Herrera S; Contreras A; Gutierrez C; Wang T; Nanda S; Giuliano M; Morrison G; Nardone A; Karlin KL; Westbrook TF; Heiser LM; Anur P; Spellman P; Guichard SM; Smith PD; Davies BR; Klinowska T; Lee AV; Mills GB; Rimawi MF; Hilsenbeck SG; Gray JW; Joshi A; Osborne CK; Schiff R
Breast Cancer Res; 2014 Sep; 16(5):430. PubMed ID: 25212826
[TBL] [Abstract][Full Text] [Related]
18. Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice.
Lenferink AE; Simpson JF; Shawver LK; Coffey RJ; Forbes JT; Arteaga CL
Proc Natl Acad Sci U S A; 2000 Aug; 97(17):9609-14. PubMed ID: 10931950
[TBL] [Abstract][Full Text] [Related]
19. A minireview: the role of MAPK/ERK and PI3K/Akt pathways in thyroid follicular cell-derived neoplasm.
Brzezianska E; Pastuszak-Lewandoska D
Front Biosci (Landmark Ed); 2011 Jan; 16(2):422-39. PubMed ID: 21196179
[TBL] [Abstract][Full Text] [Related]
20. Stat5 regulates the phosphatidylinositol 3-kinase/Akt1 pathway during mammary gland development and tumorigenesis.
Schmidt JW; Wehde BL; Sakamoto K; Triplett AA; Anderson SM; Tsichlis PN; Leone G; Wagner KU
Mol Cell Biol; 2014 Apr; 34(7):1363-77. PubMed ID: 24469394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]